Capítulo 3 Operaciones de Digitalizaciones Básicas
3.4 Cambio de Configuraciones de Digitalización
A key point that distinguishes the PRGF-Endoret technology from other PRP products is its versatility. Four different for- mulations (Fig. 3) with therapeutic potential are obtained from the patient’s blood, depending on the coagulation and activation degree of the samples. These formulations may be used for different therapeutic purposes:
1. PRGF-Endoret scaffold. It is a 3-dimensional matrix, encloses autologous growth factors, both plasma and platelet proteins. This scaffold can be used in various applications, such as the treatment of ulcers,85,86
wound closure, and tissue engineering.87 The 3-
dimensional structure of the fibrin mesh (Fig. 4) al- lows cell proliferation because, as mentioned earlier, it contains factors necessary for growth and migra- tion of cells. In addition, this formulation can be combined with other materials,88such as autologous
bone, demineralized freeze-dried bovine bone, col- lagen among others, adjusting the resulting charac- teristics of the scaffold.
2. Liquid PRGF-Endoret, activated at the time of use, is used in intra-articular injections,89,90surgery,91,92treat-
ment of skin disorders,85,86 skin regeneration,93 and
implant surface bioactivation by producing a biologi- cally active layer on the titanium surfaces.94
3. The PRGF-Endoret supernatant contains plasma pro- teins and platelet releasate, and can be used as eye-drop treatment for dry eye disease95and other corneal de-
fects.96In both basic and applied studies, this formula-
tion can be used to supplement the cell culture me- dium.76,97,98
4. Autologous fibrin membrane. At the end of the process of coagulation, fibrin scaffold retracts. At that stage, the fibrin membrane can be shaped with tweezers or simi- lar instruments to obtain an elastic, dense, and sutur- able membrane. It is an excellent tool to seal the postex- traction tooth sockets99 and to promote the full
epithelialization of soft tissues.100
The autologous platelet products have a high therapeutic potential and can be used in various formulations and in various fields of medicine and tissue engineering. At present, there are over 40 of these products with different character- istics, in terms of enrichment of platelets, presence of leuko- cytes, kind of activator, and final volume among others. This great variability makes it difficult to standardize protocols
and compare results. Furthermore, this large variability can engender confusion among clinicians and researchers.101It
is, therefore, necessary to reach a consensus and better defi- nition of each product. Our research team has spent more than 15 years developing this technology, which makes PRGF-Endoret one of the best characterized autologous PRP, with multiple and growing therapeutic applications, as result of a continuous research translation to the clinic setting.
References
1. Maffulli N, Longo UG, Denaro V: Novel approaches for the manage- ment of tendinopathy. J Bone Joint Surg Am 92:2604-2613, 2010 2. Anitua E, Sánchez M, Nurden AT, et al: New insights into and novel
applications for platelet-rich fibrin therapies. Trends Biotechnol 24: 227-234, 2006
3. Werner S, Grose R: Regulation of wound healing by growth factors and cytokines. Physiol Rev 83:835-870, 2003
4. Singer AJ, Clark RA: Cutaneous wound healing. N Engl J Med 341: 738-746, 1999
5. Beanes SR, Dang C, Soo C, et al: Skin repair and scar formation: The central role of TGF-beta. Expert Rev Mol Med 5:1-22, 2003
Figure 4 Three-dimensional structure of PRGF-Endoret fibrin net-
work. (A) Network of fibrin and platelet aggregates scattered throughout the network of fibrin. May-Grunwald-Giemsa staining. (B) Detail of the tridimensional structure of the fibrin network. Note the interconnected intact fibrin strands. Scanning electron micros- copy. Original magnifications (A, x400; B, x3500).
6. Satish L, Kathju S: Cellular and molecular characteristics of scarless versus fibrotic wound healing. Dermatol Res Pract 2010:790234, 2010
7. Karalaki M, Fili S, Philippou A, et al: Muscle regeneration: Cellular and molecular events. In Vivo 23:779-796, 2009
8. Oliva F, Via AG, Maffulli N: Role of growth factors in rotator cuff healing. Sports Med Arthrosc 19:218-226, 2011
9. Soucacos PN, Johnson EO, Babis G: An update on recent advances in bone regeneration. Injury 39 (suppl 2):S1-S4, 2008
10. Deschaseaux F, Sensébé L, Heymann D: Mechanisms of bone repair and regeneration. Trends Mol Med 15:417-429, 2009
11. Fortier LA, Barker JU, Strauss EJ, et al: The role of growth factors in cartilage repair. Clin Orthop Relat Res 469:2706-2715, 2011 12. Barrientos S, Stojadinovic O, Golinko MS, et al: Growth factors and
cytokines in wound healing. Wound Repair Regen 16:585-601, 2008 13. Dereka XE, Markopoulou CE, Vrotsos IA: Role of growth factors on
periodontal repair. Growth Factors 24:260-267, 2006
14. Raja S, Byakod G, Pudakalkatti P: Growth factors in periodontal re- generation. Int J Dent Hyg 7:82-89, 2009
15. Yu FS, Yin J, Xu K, et al: Growth factors and corneal epithelial wound healing. Brain Res Bull 81:229-235, 2010
16. Anitua E, Sánchez M, Orive G: Potential of endogenous regenerative technology for in situ regenerative medicine. Adv Drug Deliv Rev 62:741-752, 2010
17. Nurden AT, Nurden P, Sanchez M, et al: Platelets and wound healing. Front Biosci 13:3532-3548, 2008
18. Blair P, Flaumenhaft R: Platelet alpha-granules: Basic biology and clinical correlates. Blood Rev 23:177-189, 2009
19. Mei-Dan O, Lippi G, Sánchez M, et al: Autologous platelet-rich plas- ma: A revolution in soft tissue sports injury management? Phys Sports Med 38:127-135, 2010
20. Mei-Dan O, Mann G, Maffulli N: Platelet-rich plasma: Any substance into it? Br J Sports Med 44:618-619, 2010
21. Castillo TN, Pouliot MA, Kim HJ, et al: Comparison of growth factor and platelet concentration from commercial platelet-rich plasma sep- aration systems. Am J Sports Med 39:266-271, 2011
22. Mishra A, Harmon K, Woodall J, et al: Sports medicine applications of platelet rich plasma. Curr Pharm Biotechnol 2011, Epub ahead of print
23. Sundman EA, Cole BJ, Fortier LA: Growth factor and catabolic cyto- kine concentrations are influenced by the cellular composition of platelet-rich plasma. Am J Sports Med 39:2135-2140, 2011 24. Alsousou J, Thompson M, Hulley P, et al: The biology of platelet-rich
plasma and its application in trauma and orthopaedic surgery: A re- view of the literature. J Bone Joint Surg Br 91:987-996, 2009 25. Mazzucco L, Borzini P, Gope R: Platelet-derived factors involved in
tissue repair-from signal to function. Transfus Med Rev 24:218-234, 2010
26. Clemmons DR: Structural and functional analysis of insulin-like growth factors. Br Med Bull 45:465-480, 1989
27. Yakar S, Courtland HW, Clemmons D: IGF-1 and bone: New discov- eries from mouse models. J Bone Miner Res 25:2543-2552, 2010 28. Ando Y, Jensen PJ: Epidermal growth factor and insulin-like growth
factor I enhance keratinocyte migration. J Invest Dermatol 100:633- 639, 1993
29. Haase I, Evans R, Pofahl R, et al: Regulation of keratinocyte shape, migration and wound epithelialization by IGF-1- and EGF-dependent signalling pathways. J Cell Sci 116:3227-3238, 2003
30. Govoni KE: Insulin-like growth factor-I molecular pathways in osteo- blasts: Potential targets for pharmacological manipulation. Curr Mol Pharmacol 2011, Epub ahead of print
31. Bikle DD, Harris J, Halloran BP, et al: Expression of the genes for insulin-like growth factors and their receptors in bone during skeletal growth. Am J Physiol 267:E278-E286, 1994
34. Heron-Milhavet L, Mamaeva D, LeRoith D, et al: Impaired muscle regeneration and myoblast differentiation in mice with a muscle-spe- cific KO of IGF-IR. J Cell Physiol 225:1-6, 2010
35. Douglas HE: TGF- in wound healing: A review. J Wound Care 19: 403-406, 2010
36. Yang EY, Moses HL: Transforming growth factor beta 1-induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane. J Cell Biol 111:731-741, 1990 37. Zhao L, Jiang S, Hantash BM: Transforming growth factor beta1 in-
duces osteogenic differentiation of murine bone marrow stromal cells. Tissue Eng Part A 16:725-733, 2010
38. Schmidt MB, Chen EH, Lynch SE: A review of the effects of insulin- like growth factor and platelet derived growth factor on in vivo carti- lage healing and repair. Osteoarthritis Cartilage 14:403-412, 2006 39. Tumia NS, Johnstone AJ: Platelet derived growth factor-AB enhances
knee meniscal cell activity in vitro. Knee 16:73-76, 2009
40. Canalis E, Varghese S, McCarthy TL, et al: Role of platelet derived growth factor in bone cell function. Growth Regul 2:151-155, 1992 41. Hock JM, Canalis E: Platelet-derived growth factor enhances bone cell
replication, but not differentiated function of osteoblasts. Endocrinol- ogy 134:1423-1428, 1994
42. Caplan AI, Correa D: PDGF in bone formation and regeneration: New insights into a novel mechanism involving MSCs. J Orthop Res 29: 1795-1803, 2011
43. Nakamura T: Structure and function of hepatocyte growth factor. Prog Growth Factor Res 3:67-85, 1991
44. Matsumoto K, Nakamura T: Hepatocyte growth factor (HGF) as a tissue organizer for organogenesis and regeneration. Biochem Biophys Res Commun 239:639-644, 1997
45. Mizuno S, Kurosawa T, Matsumoto K, et al: Hepatocyte growth factor prevents renal fibrosis and dysfunction in a mouse model of chronic renal disease. J Clin Invest 101:1827-1834, 1998
46. Shang J, Deguchi K, Ohta Y, et al: Strong neurogenesis, angiogenesis, synaptogenesis, and antifibrosis of hepatocyte growth factor in rats brain after transient middle cerebral artery occlusion. J Neurosci Res 89:86-95, 2011
47. Shukla MN, Rose JL, Ray R, et al: Hepatocyte growth factor inhibits epithelial to myofibroblast transition in lung cells via Smad7. Am J Respir Cell Mol Biol 40:643-453, 2009
48. Bao P, Kodra A, Tomic-Canic M, et al: The role of vascular endothelial growth factor in wound healing. J Surg Res 153:347-358, 2009 49. Ferrara N, Gerber HP: The role of vascular endothelial growth factor
in angiogenesis. Acta Haematol 106:148-156, 2001
50. Luo J, Xiong Y, Han X, et al: VEGF non-angiogenic functions in adult organ homeostasis: Therapeutic implications. J Mol Med (Berl) 89: 635-645, 2011
51. Song SY, Chung HM, Sung JH: The pivotal role of VEGF in adipose- derived-stem-cell-mediated regeneration. Expert Opin Biol Ther 10: 1529-1537, 2010
52. Carpenter G, Cohen S: Epidermal growth factor. J Biol Chem 265: 7709-7712, 1990
53. Kurten RC, Chowdhury P, Sanders RC Jr, et al: Coordinating epider- mal growth factor-induced motility promotes efficient wound closure. Am J Physiol Cell Physiol 288:C109-C121, 2005
54. Schultz G, Rotatori DS, Clark W: EGF and TGF-alpha in wound healing and repair. J Cell Biochem 45:346-352, 1991
55. Schultz G, Chegini N, Grant M, et al: Effects of growth factors on corneal wound healing. Acta Ophthalmol Suppl 202:60-66, 1992 56. Wong RW, Guillaud L: The role of epidermal growth factor and its
receptors in mammalian CNS. Cytokine Growth Factor Rev 15:147- 156, 2004
57. Xian CJ, Zhou XF: EGF family of growth factors: Essential roles and functional redundancy in the nerve system. Front Biosci 9:85-92,
59. Klagsbrun M: The fibroblast growth factor family: Structural and bi- ological properties. Prog Growth Factor Res 1:207-235, 1989 60. Yun YR, Won JE, Jeon E, et al: Fibroblast growth factors: Biology,
function, and application for tissue regeneration. J Tissue Eng 2010: 218142, 2010
61. Tabata Y, Yamada K, Hong L, et al: Skull bone regeneration in pri- mates in response to basic fibroblast growth factor. J Neurosurg 91: 851-856, 1999
62. Song K, Rao NJ, Chen ML, et al: Enhanced bone regeneration with sequential delivery of basic fibroblast growth factor and sonic hedge- hog. Injury 42:796-802, 2011
63. Kempen DH, Creemers LB, Alblas J, et al: Growth factor interactions in bone regeneration. Tissue Eng Part B Rev 16:551-566, 2010 64. Chang J, Most D, Thunder R, et al: Molecular studies in flexor tendon
wound healing: The role of basic fibroblast growth factor gene expres- sion. J Hand Surg Am 23:1052-1058, 1998
65. Thomopoulos S, Das R, Sakiyama-Elbert S, et al: bFGF and PDGF-BB for tendon repair: Controlled release and biologic activity by tendon fibroblasts in vitro. Ann Biomed Eng 38:225-234, 2010
66. Shimabukuro Y, Ichikawa T, Terashima Y, et al: Basic fibroblast growth factor regulates expression of heparan sulfate in human peri- odontal ligament cells. Matrix Biol 27:232-241, 2008
67. Shirakata Y, Taniyama K, Yoshimoto T, et al: Regenerative effect of basic fibroblast growth factor on periodontal healing in two-wall in- trabony defects in dogs. J Clin Periodontol 37:374-381, 2010 68. Murakami S: Periodontal tissue regeneration by signaling molecule(s):
What role does basic fibroblast growth factor (FGF-2) have in peri- odontal therapy? Periodontol 2000 56:188-208, 2011
69. Annes JP, Munger JS, Rifkin DB: Making sense of latent TGFbeta activation. J Cell Sci 116:217-224, 2003
70. Bielecki TM, Gazdzik TS, Arendt J, et al: Antibacterial effect of autol- ogous platelet gel enriched with growth factors and other active sub- stances: An in vitro study. J Bone Joint Surg Br 89:417-420, 2007 71. Anitua E, Alonso R, Girbau C, et al: Antibacterial effect of plasma rich
in growth factors (PRGF-Endoret) against Staphylococcus aureus and epidermidis strains. Clin Exp Dermatol (in press)
72. El-Sharkawy H, Kantarci A, Deady J, et al: Platelet-rich plasma: Growth factors and pro- and anti-inflammatory properties. J Peri- odontol 78:661-669, 2007
73. Bendinelli P, Matteucci E, Dogliotti G, et al: Molecular basis of anti- inflammatory action of platelet-rich plasma on human chondrocytes: Mechanisms of NF- B inhibition via HGF. J Cell Physiol 225:757- 766, 2010
74. Lesurtel M, Graf R, Aleil B, et al: Platelet-derived serotonin mediates liver regeneration. Science 312:104-107, 2006
75. Anitua E, Sánchez M, Prado R, et al: Plasma rich in growth factors: The pioneering autologous technology for tissue regeneration. J Biomed Mater Res A 97:536, 2011
76. Anitua E, Sánchez M, Zalduendo MM, et al: Fibroblastic response to treatment with different preparations rich in growth factors. Cell Pro- lif 42:162-170, 2009
77. Weibrich G, Hansen T, Kleis W, et al: Effect of platelet concentration in platelet-rich plasma on peri-implant bone regeneration. Bone 34: 665-671, 2004
78. Zehnder JL, Leung LL: Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin. Blood 76:2011-2016, 1990
79. Landesberg R, Moses M, Karpatkin M: Risks of using platelet rich plasma gel. J Oral Maxillofac Surg 56:1116-1117, 1998
80. Diesen DL, Lawson JH: Bovine thrombin: History, use, and risk in the surgical patient. Vascular 16(suppl 1):S29-S36, 2008
81. Weibrich G, Kleis WK, Hitzler WE, et al: Comparison of the platelet concentrate collection system with the plasma-rich-in-growth-factors
kit to produce platelet-rich plasma: A technical report. Int J Oral Maxillofac Implants 20:118-123, 2005
82. Scott A, Khan KM, Roberts CR, et al: What do we mean by the term “inflammation”? A contemporary basic science update for sports med- icine. Br J Sports Med 38:372-380, 2004
83. Tidball JG: Inflammatory processes in muscle injury and repair. Am J Physiol Regul Integr Comp Physiol 288:R345-R353, 2005 84. Harmon KG: Muscle injuries and PRP: What does the science say? Br J
Sports Med 44:616-617, 2010
85. Orcajo B, Muruzabal F, Isasmendi MC, et al: The use of plasma rich in growth factors (PRGF-Endoret) in the treatment of a severe mal per- forant ulcer in the foot of a person with diabetes. Diabetes Res Clin Pract 93:e65-e677, 2011
86. Anitua E, Aguirre JJ, Algorta J, et al: Effectiveness of autologous prep- aration rich in growth factors for the treatment of chronic cutaneous ulcers. J Biomed Mater Res B Appl Biomater 84:415-421, 2008 87. Anitua E, Sanchez M, Nurden AT, et al: Autologous fibrin matrices: A
potential source of biological mediators that modulate tendon cell activities. J Biomed Mater Res A 77:285-293, 2006
88. Anitua E, Prado R, Orive G: A lateral approach for sinus elevation using PRGF technology. Clin Implant Dent Relat Res 11 (suppl 1): e23-e31, 2009
89. Sánchez M, Anitua E, Azofra J, et al: Intra-articular injection of an autologous preparation rich in growth factors for the treatment of knee OA: A retrospective cohort study. Clin Exp Rheumatol 26:910- 913, 2008
90. Wang-Saegusa A, Cugat R, Ares O, et al: Infiltration of plasma rich in growth factors for osteoarthritis of the knee short-term effects on function and quality of life. Arch Orthop Trauma Surg 131:311-317, 2011
91. Sanchez M, Anitua E, Cugat R, et al: Nonunions treated with autolo- gous preparation rich in growth factors. J Orthop Trauma 23:52-59, 2009
92. Seijas R, Santana-Suarez RY, Garcia-Balletbo M, et al: Delayed union of the clavicle treated with plasma rich in growth factors. Acta Orthop Belg 76:689-693, 2010
93. Anitua E, Sánchez M, Sarabia R, et al: Eficacia y seguridad del PRGF® (plasma rico en factores de crecimiento) en la regeneración cutánea facial. Ensayo clínico, randomizado y controlado con ácido hi- alurónico. Revista de la AECEP 12:23-33, 2010
94. Anitua EA: Enhancement of osseointegration by generating a dynamic implant surface. J Oral Implantol 32:72-76, 2006
95. López-Plandolit S, Morales MC, Freire V, et al: Plasma rich in growth factors as a therapeutic agent for persistent corneal epithelial defects. Cornea 29:843-848, 2010
96. Alio JL, Abad M, Artola A, et al: Use of autologous platelet-rich plasma in the treatment of dormant corneal ulcers. Ophthalmology 114: 1286-1293, 2007
97. Johansson L, Klinth J, Holmqvist O, et al: Platelet lysate: A replace- ment for fetal bovine serum in animal cell culture? Cytotechnology 42:67-74, 2003
98. Anitua E, Sanchez M, Merayo-Lloves J, et al: Plasma rich in growth factors (PRGF-Endoret) stimulates proliferation and migration of pri- mary keratocytes and conjunctival fibroblasts and inhibits and reverts TGF-beta1-induced myodifferentiation. Invest Ophthalmol Vis Sci 52:6066-6073, 2011
99. Rosano G, Taschieri S, Del Fabbro M: Immediate post-extraction im- plant placement using PRGF technology in maxillary premolar region: A new strategy for soft tissue management. J Oral Implantol 2011, Epub ahead of print
100. Sánchez M, Anitua E, Cole A, et al: Management of post-surgical Achilles tendon complications with a preparation rich in growth fac- tors: A study of two-cases. Inj Extra 40:11-15, 2009
101. Anitua E, Sánchez M, Prado R, et al: The P makes the difference in plasma rich in growth factors (PRGF) technology. Platelets 22:473- 474, 2011